Population pharmacokinetics of vancomycin in Japanese pediatric patients.

The population pharmacokinetic profile of vancomycin (VCM) in Japanese pediatric patients infected with methicillin-resistant Staphylococcus aureus was analyzed using 181 samples of serum concentration data from 49 patients obtained in routine drug monitoring. The one-compartment linear model was adopted, where the VCM clearance (CL) and the distribution volume (Vd) were correlated with covariates such as postnatal age (AGE) and body weight (BWT). The population pharmacokinetic analysis program NONMEM with the first-order conditional estimation method was used. The results showed that the population mean clearance normalized by BWT increases with AGE up to 1 year of age [CL(L/hour per kg) = 0.1 19 + 0.0619 x (AGE - 1)] and decreases with age over 1 year old [CL(L/hour per kg) = 0.119 + 0.00508 x (1 - AGE)]. The population mean of the distribution volume normalized by BWT was independent of AGE (Vd (L/kg) = 0.522). The interindividual variability of CL was 39.6%, and that of Vd was 18.8%. The intraindividual, residual variability was 34.6%. These results were compared with those in other articles, and a guideline for dosage adjustment in VCM therapy is discussed.

[1]  K. Rodvold,et al.  Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children , 1997, Clinical pharmacokinetics.

[2]  J. M. Lanao,et al.  Bayesian Forecasting in Paediatric Populations , 1996, Clinical pharmacokinetics.

[3]  R. Hatala,et al.  Once-Daily Aminoglycoside Dosing in Immunocompetent Adults , 1996, Annals of Internal Medicine.

[4]  D. Chang.  Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. , 1995, The Pediatric infectious disease journal.

[5]  K. Rodvold,et al.  Bayesian Forecasting of Serum Vancomycin Concentrations in Neonates and Infants , 1995, Therapeutic drug monitoring.

[6]  W. Leader,et al.  Pharmacokinetic Optimisation of Vancomycin Therapy , 1995, Clinical pharmacokinetics.

[7]  M. Malogolowkin,et al.  A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. , 1994, The Pediatric infectious disease journal.

[8]  R. Slaughter,et al.  Vancomycin Pharmacokinetics in a Patient Population: Effect of Age, Gender, and Body Weight , 1994, Therapeutic drug monitoring.

[9]  R. Brundage,et al.  Population pharmacokinetics of vancomycin in neonates , 1994, Clinical pharmacology and therapeutics.

[10]  J. Rotschafer,et al.  A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient. , 1994, The Journal of antimicrobial chemotherapy.

[11]  D. Guay,et al.  Bayesian Forecasting of Serum Vancomycin Concentrations with Non‐Steady‐State Sampling Strategies , 1994, Therapeutic drug monitoring.

[12]  J. Rotschafer,et al.  Comparison of Vancomycin Pharmacokinetics in Hospitalized Elderly and Young Patients Using a Bayesian Forecaster , 1993, Journal of clinical pharmacology.

[13]  John E. Murphy,et al.  Vancomycin Pharmacokinetics in Neonates and Infants: A Retrospective Evaluation , 1993, The Annals of pharmacotherapy.

[14]  J. Rotschafer,et al.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique , 1993, Antimicrobial Agents and Chemotherapy.

[15]  W. Macias,et al.  Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance , 1991, Clinical pharmacology and therapeutics.

[16]  P. Marik,et al.  A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. , 1991, The Journal of antimicrobial chemotherapy.

[17]  K. Rodvold,et al.  An Updated Comparison of Drug Dosing Methods , 1991, Clinical pharmacokinetics.

[18]  M. Rybak,et al.  Nephrotoxicity of vancomycin, alone and with an aminoglycoside. , 1990, The Journal of antimicrobial chemotherapy.

[19]  E. Lee,et al.  Pharmacokinetics of Intravenous Vancomycin in Patients with End‐Stage Renal Failure , 1990, Therapeutic drug monitoring.

[20]  J. Rotschafer,et al.  Evaluation of a Two‐Compartment Bayesian Forecasting Program for Predicting Vancomycin Concentrations , 1989, Therapeutic drug monitoring.

[21]  J. Rotschafer,et al.  Simulation of Vancomycin Peak and Trough Concentrations Using Five Dosing Methods in 37 Patients , 1989, Pharmacotherapy.

[22]  J. Rotschafer,et al.  Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. , 1989, Therapeutic drug monitoring.

[23]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[24]  W. Bennett,et al.  Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects , 1988, Clinical pharmacology and therapeutics.

[25]  L. S. Mauro,et al.  Vancomycin dosing chart for use in patients with renal impairment. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  R. Slaughter,et al.  Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. , 1987, The American journal of medicine.

[27]  D. Brater,et al.  Bayesian and Least‐Squares Methods for Vancomycin Dosing , 1987, The American journal of the medical sciences.

[28]  G. Koren,et al.  Vancomycin pharmacokinetics and dose recommendations for preterm infants , 1987, Antimicrobial Agents and Chemotherapy.

[29]  G. Matzke,et al.  Clinical Pharmacokinetics of Vancomycin , 1986, Clinical pharmacokinetics.

[30]  R. Polin,et al.  Vancomycin pharmacokinetics in infants: relationships to indices of maturation. , 1986, Pediatric infectious disease.

[31]  K. Lake,et al.  A Simplified Dosing Method for Initiating Vancomycin Therapy , 1985, Pharmacotherapy.

[32]  L. Lesko,et al.  Vancomycin disposition: The importance of age , 1984, Clinical pharmacology and therapeutics.

[33]  W. Keane,et al.  Pharmacokinetics of vancomycin in patients with various degrees of renal function , 1984, Antimicrobial Agents and Chemotherapy.

[34]  R. Moellering.  Pharmacokinetics of vancomycin. , 1984, The Journal of antimicrobial chemotherapy.

[35]  G. Bodey,et al.  Effects of hepatic function on vancomycin clinical pharmacology , 1983, Antimicrobial Agents and Chemotherapy.

[36]  J. Jui,et al.  Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. , 1982, Annals of internal medicine.

[37]  T. Sorrell,et al.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus. , 1982, Annals of internal medicine.

[38]  P. Traber,et al.  Vancomycin Ototoxicity in patient with normal renal function. , 1981, Annals of Internal Medicine.

[39]  D J Greenblatt,et al.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. , 1981, Annals of internal medicine.

[40]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[41]  G. Mccracken,et al.  Clinical pharmacology and efficacy of vancomycin in pediatric patients. , 1980, The Journal of pediatrics.

[42]  M. Roizen,et al.  Hazards of rapid administration of vancomycin. , 1979, Annals of internal medicine.

[43]  J. Hook,et al.  Perinatal renal pharmacology. , 1979, Annual review of pharmacology and toxicology.

[44]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[45]  B. Friis‐Hansen.  Body water compartments in children: changes during growth and related changes in body composition. , 1961, Pediatrics.

[46]  H. L. Barnett,et al.  Kidney function in young infants. , 1950, Pediatrics.